All news articles for November 2021

© GettyImages/CiydemImages

Ncardia secures $60m to expand iPSC platform

By Jane Byrne

Ncardia, a human-induced pluripotent stem cell-based (iPSC) technology company, has secured more than US$60m in capital through a strategic partnership with Kiniciti, a US based investor with a focus on the global cell and gene therapy ecosystem.

Follow us

Products

View more

Webinars